drugset / Trial / NCT06689163
A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to observe and evaluate the tolerability, safety, and pharmacokinetics of HRS-1167 combined with abiraterone acetate tablets (II) and prednisone in patients with metastatic prostate cancer, determine the RP2D, and evaluate the effectiveness.
Timeline
- Start
- 2024-12-11
- Primary completion
- 2025-11-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HRS-1167 | Unknown | — | — |
| Background | Abiraterone acetate | Small molecule | — | — |
| Background | Prednisone | Other / unclassified | — | — |